Human Growth Hormone (hGH) Market to Incur Steady Growth $5,563 million by 2026 | CAGR 8.6%

The global human growth hormone market size is expected to reach $5,563 million by 2026, registering a CAGR of 8.6% from 2019 to 2026, in terms of value.

Artificial human growth hormones were developed in 1985 and approved by the FDA for explicit usage in children and adults. In children, growth hormones are approved to treat short height or poor growth due to several medical causes, including Turner syndrome, Prader-Willi syndrome, chronic kidney disease, and hGH deficiency. Whereas, in adults they are used to treat short bowel syndrome, hGH deficiency due to rare pituitary tumors and muscle-wasting disease related to HIV/AIDS. Further, the adoption of human growth hormone to control aging has increased over a period. Significance of human growth hormone in aging is vigorously being explored in clinical and experimental studies. Further, treatment of GH deficient adults with recombinant or artificial human GH (rhGH) improves muscle strength, body composition, physical function, and bone density. In addition, it decreases blood cholesterol and cardiovascular disease risk.

Download Report Sample @ https://www.alliedmarketresearch.com/request-toc-and-sample/5557

The Major Key Players Are:

o Novo Nordisk
o Merck & Co., Inc.
o Eli Lilly and Company
o Pfizer Inc.
o Teva Pharmaceutical Industries Ltd
o Novartis AG
o AnkeBio Co. Ltd
o F. Hoffmann-La Roche
o Ipsen
o Ferring BV.

The human growth hormone market can be segmented on the basis of application, route of administration, distribution channel, and region. By application, it is categorized into growth hormone deficiency, Prader-Willi syndrome, Turner syndrome, small for gestational age, and others. By route of administration, it is classified into intravenous, intramuscular, subcutaneous, and oral. On the basis of distribution channel, it is divided into hospital pharmacy, retail pharmacy, clinic, and online pharmacy. Region wise, it is analyzed across North America, Asia-Pacific, Europe, and LAMEA.

Significant increase in prevalence of chronic diseases including growth retardation, pituitary dysfunctions, and surge in compliance for growth hormone formulations are the major factors that drive the human growth hormone market growth. For instance, incidence of isolated growth hormone deficiency is estimated to be 1 in 4,000 to 10,000 individuals worldwide. Further, growth hormone deficiency occurs in around 1 in 7,000 live births. In addition, increased medical expenditure and disposable incomes in developing nations propels the market growth. However, the side-effects associated with the consumption of these hormones such as muscle pain, joint pain, and fluid retention; and high cost of the treatment hampers the growth of the market. Moreover, stringent government approvals are expected to restrain the growth and development of the market in the coming years.

Based on human growth hormone market analysis, by application, the Turner syndrome segment dominated the market in 2018, and is expected to exhibit a prominent growth rate in the near future, owing to the surge in its incidence across the globe. For instance, according to U.S. National Organization of Rare Disorders, it is estimated that more than 70,000 women and girls in the country have Turner syndrome.

Make an Enquiry before Buy @ https://www.alliedmarketresearch.com/purchase-enquiry/5557

By route of administration, the subcutaneous segment dominated the human growth hormone market in 2018, and is anticipated to maintain its dominance during the forecast period. This is attributed to the fact that growth hormones administered subcutaneously have more bioavailability compared to other routes of administration. Currently, most of the artificial growth hormone formulations are being made for subcutaneous route of administration.

Key Finding of The Human Growth Hormone Market:

o By application, the Turner Syndrome segment dominated the market in 2018 and is anticipated to continue the same during the forecast period.
o By region, North America was the major shareholder and accounted for the highest share of 48% in 2018.
o By route of administration, the subcutaneous segment is expected to grow at a CAGR of 9.1% during the forecast period.
o By distribution channel, the hospital pharmacy segment dominated the human growth hormone market in 2018 and is anticipated to maintain its dominance during the forecast period.

Similar Reports:

Anesthesia Devices Market: https://www.medgadget.com/2018/12/anesthesia-devices-market-analysis-of-the-global-industry-helps-to-understand-business-intelligence-practices.html

Abdominal Aortic Aneurysm (AAA) Repair Devices Market: https://www.medgadget.com/2019/03/abdominal-aortic-aneurysm-repair-devices-market-set-to-reach-2614-million-globally-by-2022.html

Contact:

David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
Toll Free (USA/Canada):
+1-800-792-5285, +1-503-894-6022, +1-503-446-1141
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1?855?550-5975
help@alliedmarketresearch.com
Web: www.alliedmarketresearch.com

About Us:

Allied Market Research, a market research and advisory company of Allied Analytics LLP, provides business insights and market research reports to large as well as small & medium enterprises. The company assists its clients to strategize business policies and achieve sustainable growth in their respective market domain.

Allied Market Research provides one stop solution from the beginning of data collection to investment advice. The analysts at Allied Market Research dig out factors that help clients to understand the significance and impact of market dynamics. The company amplies client's insight on the factors, such as strategies, future estimations, growth or fall forecasting, opportunity analysis, and consumer surveys among others. As follows, the company offers consistent business intelligent support to aid the clients to turn into prominent business firm.

This release was published on openPR.